Moderna data shows mRNA isn’t a quick fix for the flu vaccine
The first data from clinical trials of Moderna’s mRNA-based seasonal flu vaccine, released by the company Friday morning, were underwhelming
The first data from clinical trials of Moderna’s mRNA-based seasonal flu vaccine, released by the company Friday morning, were underwhelming
Based on COVID-19 ‘messenger’ RNA or mRNA vaccines, the new flu vaccines could better protect people from multiple types of...
Both Moderna and Pfizer—makers of the first vaccines to earn U.S. Food and Drug Administration (FDA) approval using the mRNA technology—are studying...